Novel DOX-MTX nanoparticles improve oral SCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: Oral and IV modalities

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6227-6232

  Abbasi, Mehran Mesgari ^a,b   Monfaredan, Amir ^c   Hamishehkar, Hamed ^a   Seidi, Khaled ^b   Jahanban Esfahlan, Rana ^b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

DOX MTX NPs; Oral and IV modalities; Oral squamous cell carcinoma (OSCC); VEGF C

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ANTINEOPLASTIC AGENT; CARCINOGEN; DOXORUBICIN; MESSENGER RNA; METHOTREXATE; NANOPARTICLE; VASCULOTROPIN C;

ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; CHEMISTRY; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECTS; ENZYME IMMUNOASSAY; GENETICS; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METABOLISM; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORAL DRUG ADMINISTRATION; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY; SPRAGUE DAWLEY RAT;

4-NITROQUINOLINE-1-OXIDE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOGENS; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; DOXORUBICIN; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MALE; METHOTREXATE; MOUTH NEOPLASMS; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84906240948     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6227     Document Type: Article

References (44)

1. Albano PM, Lumang-Salvador C, Orosa J 3rd, et al (2013). Overall survival of Filipino patients with squamous cell carcinoma of the head and neck: a single-institution experience. Asian Pac J Cancer Prev, 14, 4769-74.
2. Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61.
3. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007). Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg, 65, 229-236.
4. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007). Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm, 423, 554-561.
5. Chen Y, Wan Y, Wang Y, Zhang H, Jiao Z (2011). Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine, 6, 2321-26.
6. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R (2014). Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. current and emerging paradigms. Clin Ther, 36, 427-35.
7. Colleoni M, Rocca A, Sandri MT, et al (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13, 73-80.
8. Deng Y, Zhang H (2013). The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics. Int J Nanomedicine, 8, 1835-41.
9. Duong HH, Yung LY (2013). Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int J Pharm, 454, 489-95.
10. Gibson RJ, Bowen JM, Cummins AG, Keefe DM (2005). Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med, 4, 188-95.
11. Han W, Yang X, Huang X, Hu Q, Wang Z (2008). Metastases to lingual lymph nodes from squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg, 46, 376-78.
12. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K (1989). Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum, 32, 1065-73.
13. Hu CM, Aryal S, Zhang L (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv, 1, 323-34.
14. Huang WY, Yang P M, Chang YF, Marquez VE, Chen CC (2011). Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol, 81, 510-17.
15. Jahanban Esfahlan R, Zarghami N, Jahanban Esfahlan A, et al (2011). The possible impact of obesity on androgen, progesterone and estrogen receptors (ERα and ERβ) Gene expression in breast cancer patients. Breast Cancer, 227-37.
16. Jahanban Esfahlan R, Zarghami N, Rahmati-Yamchi M, et al (2011). Quantification of steroid receptors gene expression in breast cancer patients: possible correlation with serum level of adipocytokines. J Cancer Therapy, 2, 659-65.
17. Jahanban Esfahlan R, Zarghami N, Valiyari S, et al (2012). Adiponectin can affect ER signaling in obese breast cancer patients. J Cancer Therapy, 3, 115-21.
18. Jones KR, Lodge-Rigal RD, Reddick RL, Tudor GE, Shockley WW (1992). Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg, 118, 483-5.
19. Kademani D, Bell RB, Bagheri S, et al (2005). Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg, 63, 1599-605.
20. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res., 26, 492-501.
21. Lasrado S, Moras K, Pinto GJ, et al. (2014). Role of concomitant chemoradiation in locally advanced head and neck cancers. Asian Pac J Cancer Prev, 15, 4147-52.
22. Liboiron BD, Mayer LD (2014). Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv, 5, 149-71.
23. Liu F, Tan G, Li J, et al (2007). Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci, 98, 1381-7.
24. Liu F, Wang P, Jiang X, et al (2008). Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci, 99, 2055-61.
25. Massano J, Regateiro FS, Januario G, Ferreira A (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, 67-76.
26. Mehdipour M, Taghavi ZA, Mesgari AM, et al (2013). Evaluation of the effect of two systemic doses of HESA-A on prevention of induced tongue neoplasm in rats. J Dent Res Dent Clin Dent Prospects, 7, 218-24.
27. Mohamed KM, Le A, Duong H, et al (2004). Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol, 76, 143-52.
28. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-28.
29. Montoro JR, Ricz HA, Souza L, et al (2008). Prognostic factors in squamous cell carcinoma of the oral cavity. Braz J Otorhinolaryngol, 74, 861-6.
30. Nasiri M, Nejati NZ, Koshki K, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pacific J Cancer Prev, 14, 3449-3453.
31. Park SK, Kim HI, Yang YI, Hur DY (2011). Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps. Am J Rhinol Allergy, 25, e129-e32.
32. Rossi B, Schinzari G, Maccauro G, et al (2010). Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord, 11, 34.
33. Rusthoven KE, Raben D, Song JI, et al (2010). Survival and patterns of relapse in patients with oral tongue cancer. J. Oral Maxillofac. Surg., 68, 584-589.
34. Salehi R, Hamishehkar H, Eskandani M, Mahkam M, Davaran S (2014). Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J Drug Target, 22, 327-42.
35. Schliephake H (2003). Prognostic relevance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg, 32, 233-45.
36. Shaker OG, Khairallah M, Rasheed HM, et al (2013). Antiangiogenic effect of methotrexate and PUVA on psoriasis. Cell Biochem. Biophys, 67, 735-42.
37. Shintani S, Li C, Ishikawa T, et al (2004). Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol, 40, 13-20.
38. Srivastava VK, Gara Rk Fau, Rastogi N, et al (2014). Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev, 15, 3261-65.
39. Sugiura T, Inoue Y, Matsuki R, et al (2009). VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker. Int J Oncol, 34, 673-80.
40. Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol, 65, 157-70.
41. Uehara M, Sano K, Ikeda H, et al (2004). Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncol, 40, 321-32.
42. Wang Y, Wei X, Zhang C, Zhang F, Liang W (2010). Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Ther Deliv, 1, 273-87.
43. Zhao SF, Yang XD, Lu MX, et al (2013). Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature. Tumour Biol, 34, 3165-71.
44. Zwetyenga N, Majoufre-Lefebvre C, Siberchicot F, Demeaux H, Insolle J (2003). Squamous-cell carcinoma of the tongue: treatment results and prognosis. Rev Stomatol Chir Maxillofac, 104, 10-17.